Korea's Cancer Survival Rates Compared with Other Countries (2026 Update)

Comparing the National Cancer Registry Statistics for 2019–2023 with the U.S. SEER data for 2016–2022 by cancer type shows that Korea's 5-year relative survival rates are higher in most categories. However, both figures represent national averages rather than the performance of any single hospital, and neither predicts an individual's outcome.

Key Takeaways

• Stomach cancer: Korea 78.6% vs. U.S. 39.8% (National Cancer Registry Statistics 2019–2023 vs. SEER 2016–2022); Korea runs a national screening program offering gastric endoscopy every 2 years starting at age 40.
• Liver cancer: Korea 40.4% vs. U.S. 21.9%; Korea provides national screening with ultrasound and blood tests every 6 months for people with hepatitis B or cirrhosis.
• Lung cancer: Korea 42.5% (up 30 percentage points from 1993–1995) vs. U.S. 29.5%; this is attributed to expanded low-dose CT screening and advances in targeted and immunotherapy.
• Colorectal cancer: Korea 75.6% vs. U.S. 65.4%. Breast cancer: Korea 94.7% vs. U.S. 91.9%. Blood cancers (all leukemias): Korea 55.7% vs. U.S. 68.6% — an example where the U.S. figure is higher.
• All figures are nationwide statistics, not the performance of any individual hospital; under Korean medical law, hospital-specific outcome data cannot be used in advertising.

Why does Korea's survival rate generally appear higher?

• Direct answer: This isn't purely a matter of treatment technology — how early the cancer is detected plays a major role. Korea operates national screening programs including gastric endoscopy (every 2 years from age 40), fecal occult blood testing for colorectal cancer (annually from age 50), ultrasound for high-risk liver cancer groups (every 6 months), mammography (every 2 years from age 40), and low-dose CT screening for lung cancer — contributing to a relatively high rate of early detection.
• That said, the note also states that simple comparisons are difficult because stage distribution at diagnosis and the composition of cancer subtypes (for example, the ratio of acute to chronic leukemia, or age at diagnosis) differ by country. Blood cancer is one case where the U.S. figure is higher, so it would be an oversimplification to conclude that 'Korea is always higher.'

Can these survival figures be applied directly to my own situation?

• Direct answer: No. Survival rates are population averages, not predictions of an individual outcome.
• For example, in breast cancer, the course and treatment differ greatly depending on hormone receptor and HER2 status; in blood cancers, it matters whether the disease is leukemia, lymphoma, or multiple myeloma, and which subtype or risk group applies; in liver cancer, liver function grade (Child-Pugh) matters even under the same diagnosis. Therefore, your own stage, subtype, and health status are more meaningful for gauging your actual prognosis than the overall average survival rate for the cancer type — and this can only be confirmed through consultation with your treating medical team.

What is the process for checking cancer-type-specific statistics?

• Step 1: Identify the cancer type — figures for stomach, colorectal, liver, lung, breast, and blood cancers from the National Cancer Registry Statistics 2019–2023, as summarized in the note, serve as reference data.
• Step 2: Confirm that the data being compared covers the same period and methodology — this article matches Korea's National Cancer Registry Statistics 2019–2023 against the U.S. SEER 2016–2022.
• Step 3: Factor in individual details such as stage and subtype — interpretation should be based on your own test results, not the overall average.
• Step 4: Consult your medical team — decisions on diagnosis and treatment method must always go through your physician's judgment.

FAQ — Can Korean and U.S. statistics be compared directly?

A full, direct comparison is difficult. The National Cancer Registry Statistics and SEER cover different periods (2019–2023 vs. 2016–2022), and both the stage distribution at diagnosis and the detailed subtype composition within a cancer type (for example, the ratio of acute to chronic leukemia) vary by country. This is why the note explicitly states that 'both figures are nationwide statistics, not the performance of any hospital,' and that 'simple comparison is difficult.' These numbers are best used as a general directional reference, and caution is needed before drawing absolute conclusions about which country is superior.

FAQ — Do individual hospitals publish different survival rates?

Under Korean medical law, individual hospitals' treatment outcomes are not used in advertising. All figures cited in this article come from the National Cancer Registry Statistics 2019–2023, compiled by the National Cancer Information Center, and do not reflect the performance of any specific hospital or medical team. An individual's treatment outcome varies by stage, subtype, age, and coexisting conditions.

Sources and Notes

• This article is based on the National Cancer Registry Statistics 2019–2023 (Korea Central Cancer Registry, National Cancer Center), U.S. SEER 2016–2022, and materials from the National Cancer Information Center of the National Cancer Center.
• This content is provided for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment decisions should always be made in consultation with your medical team.